Shoulder Innovations Inc (SI)

NYSE · Healthcare · Medical Devices · USA

Shoulder Innovations Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Shoulder Innovations provides prosthetic implant systems for shoulder joint reconstruction procedures. Its product ecosystem comprises preoperative imaging software called ProVoyance, streamlined surgical instrument trays, dedicated surgeon specialists, and a community network for peer learning. The company serves surgeons and patients undergoing shoulder replacement operations in both hospital and outpatient surgical centers.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Shoulder Innovations Inc stock.

Our verdict on SI

Not valued: We cannot value this company yet.

We do not publish a value for this company: its filings cover two fiscal years and projecting growth needs four in a row.

ETFs with the most weight in SI

11 more funds hold it; the full list is part of the paid plan.

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than SI in Medical Devices

61 more in this industry show a wider margin of safety.

Is SI undervalued or overvalued?

We do not publish a verdict on SI yet. A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.

What is the intrinsic value of SI?

We do not publish one (as of the 2026-11-17 close). A discounted cash flow projects five years of revenue, so it needs this company’s own growth history: four consecutive fiscal years of accounts, which give three year-on-year growth rates. Its filings on our archive cover two fiscal years so far; the next annual report should close the gap. We could plug in a generic rate, but that would be a valuation of an average company, not of this one.